Roundview Capital LLC Sells 4,381 Shares of Pfizer Inc. $PFE

Roundview Capital LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 15.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,888 shares of the biopharmaceutical company’s stock after selling 4,381 shares during the period. Roundview Capital LLC’s holdings in Pfizer were worth $603,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in PFE. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. Courier Capital LLC lifted its position in shares of Pfizer by 3.2% in the 1st quarter. Courier Capital LLC now owns 53,033 shares of the biopharmaceutical company’s stock worth $1,344,000 after purchasing an additional 1,666 shares during the period. City Holding Co. lifted its position in shares of Pfizer by 6.9% in the 1st quarter. City Holding Co. now owns 36,224 shares of the biopharmaceutical company’s stock worth $918,000 after purchasing an additional 2,352 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in shares of Pfizer by 44.1% in the 1st quarter. Farther Finance Advisors LLC now owns 85,290 shares of the biopharmaceutical company’s stock worth $2,093,000 after purchasing an additional 26,095 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on PFE. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.41.

Pfizer Stock Down 0.6%

NYSE:PFE opened at $26.27 on Wednesday. The firm has a market capitalization of $149.36 billion, a P/E ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company’s fifty day moving average price is $24.76 and its 200-day moving average price is $24.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.